MAXHEALTH - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.2
| Stock Code | MAXHEALTH | Market Cap | 95,276 Cr. | Current Price | 979 ₹ | High / Low | 1,314 ₹ |
| Stock P/E | 135 | Book Value | 87.3 ₹ | Dividend Yield | 0.15 % | ROCE | 12.5 % |
| ROE | 9.45 % | Face Value | 10.0 ₹ | DMA 50 | 1,043 ₹ | DMA 200 | 1,088 ₹ |
| Chg in FII Hold | -1.25 % | Chg in DII Hold | 1.17 % | PAT Qtr | 200 Cr. | PAT Prev Qtr | 160 Cr. |
| RSI | 32.8 | MACD | -16.9 | Volume | 29,73,107 | Avg Vol 1Wk | 49,74,219 |
| Low price | 934 ₹ | High price | 1,314 ₹ | PEG Ratio | 4.29 | Debt to equity | 0.08 |
| 52w Index | 11.9 % | Qtr Profit Var | 5.45 % | EPS | 7.10 ₹ | Industry PE | 43.5 |
📊 Analysis: Max Healthcare shows weak-to-moderate momentum for intraday trading today. RSI at 32.8 indicates oversold conditions, while MACD is negative (-16.9), confirming bearish momentum. Current price (979 ₹) is trading below both 50 DMA (1,043 ₹) and 200 DMA (1,088 ₹), showing short-term and medium-term weakness. Volume is lower than the 1-week average, suggesting reduced participation and limited conviction in price action.
💡 Optimal Buy Price: Around 970–985 ₹ if intraday support holds.
🎯 Profit Exit Levels: 995 ₹ (first target), 1,015 ₹ (second target if momentum improves).
⚠️ Stop-Loss: 960 ₹ to protect against downside risk.
📌 If Already Holding: Consider exiting near 995–1,015 ₹ if momentum indicators remain weak. If price falls below 960 ₹ with volume confirmation, exit to avoid deeper losses.
✅ Positive
- Quarterly PAT growth (200 Cr. vs 160 Cr.).
- EPS at 7.10 ₹ supports earnings visibility.
- ROCE (12.5%) and ROE (9.45%) indicate moderate capital efficiency.
- DII holdings increased (+1.17%), showing strong domestic support.
- Debt-to-equity ratio at 0.08, low leverage.
⚠️ Limitation
- Price trading below both 50 DMA and 200 DMA, showing weakness.
- RSI and MACD indicate bearish momentum.
- PEG ratio at 4.29 indicates overvaluation relative to growth.
- Dividend yield at 0.15% is very low, limiting income appeal.
- Volume below average, limiting intraday participation.
📉 Company Negative News
- FII holdings decreased (-1.25%), showing reduced foreign confidence.
- 52-week index at 11.9% shows severe underperformance relative to highs.
📈 Company Positive News
- Quarterly profit growth of 5.45% shows operational improvement.
- DII holdings increased significantly (+1.17%), showing domestic investor confidence.
🏭 Industry
- Healthcare sector trading at PE ~43.5, Max Healthcare is overvalued with P/E of 135.
- Sector demand remains defensive, benefiting from rising healthcare needs and hospital expansion.
🔎 Conclusion
Max Healthcare is a weak intraday candidate today due to bearish technicals and overvaluation. A cautious buy near 970–985 ₹ with targets at 995 ₹ and 1,015 ₹ offers limited opportunity, but traders should maintain a strict stop-loss at 960 ₹. Better suited for swing trades if price sustains above 1,043 ₹ (50 DMA) with improving momentum.
Would you like me to prepare a peer benchmarking overlay with other hospital and healthcare stocks (like Apollo Hospitals, Fortis Healthcare, Narayana Hrudayalaya) so you can compare Max Healthcare’s intraday strength against sector leaders?